{"id":"av-001","safety":{"commonSideEffects":[{"rate":"10-20%","effect":"Fatigue"},{"rate":"5-10%","effect":"Diarrhea"},{"rate":"5-10%","effect":"Nausea"}]},"_chembl":{"chemblId":"CHEMBL3939716","moleculeType":"Small molecule","molecularWeight":"415.41"},"_dailymed":null,"mechanism":{"_ai_source":"groq-llama-8b","explanation":"AV-001 works by inhibiting the PI3K delta subunit, which is involved in the activation of immune cells. This inhibition leads to a reduction in inflammation and an enhancement of anti-tumor immune responses. By modulating the PI3K pathway, AV-001 aims to improve the efficacy of cancer immunotherapies.","oneSentence":"AV-001 is a small molecule that targets the PI3K pathway to modulate immune responses.","_ai_confidence":"high"},"_scrapedAt":"2026-03-28T02:30:00.681Z","_scrapedBy":"cloudflare-swarm","_wikipedia":null,"indications":{"approved":[{"name":"Metastatic non-small cell lung cancer, PD-L1 positive"},{"name":"Metastatic melanoma"}]},"trialDetails":[{"nctId":"NCT05123755","phase":"PHASE2","title":"Phase 2a Multiple Ascending Dose Study in Hospitalized Patients With Pneumonia.","status":"RECRUITING","sponsor":"Vasomune Therapeutics, Inc.","startDate":"2021-12-20","conditions":"Acute Respiratory Distress Syndrome, Viral or Bacterial Infections, Pneumonia","enrollment":120},{"nctId":"NCT07234890","phase":"PHASE2","title":"Study to Evaluate the Effects of AV-001 on HD-induced Brain Injury.","status":"NOT_YET_RECRUITING","sponsor":"London Health Sciences Centre Research Institute","startDate":"2025-12-01","conditions":"Hemodialysis","enrollment":60},{"nctId":"NCT04737486","phase":"PHASE1","title":"A First-in-Human Study of AV-001 in Healthy Subjects","status":"COMPLETED","sponsor":"Vasomune Therapeutics, Inc.","startDate":"2020-12-16","conditions":"Covid19-associated ARDS, Covid19, ARDS","enrollment":48}],"_emaApprovals":[],"_faersSignals":[],"_approvalHistory":[],"publicationCount":0,"rwe":[],"genericFilers":[],"relatedDrugs":[],"labelChanges":[],"biosimilarFilings":[],"pricing":[],"formularyStatus":[],"manufacturing":[],"companionDiagnostics":[],"competitors":[],"timeline":[],"patents":[],"ownershipHistory":[],"trials":[],"biosimilars":[],"latestUpdates":[],"references":[],"tags":[],"ecosystem":[],"genericManufacturerList":[],"offLabel":[],"developmentCodes":[],"aliases":[],"phase":"phase_2","status":"active","brandName":"AV-001","genericName":"AV-001","companyName":"Vasomune Therapeutics, Inc.","companyId":"vasomune-therapeutics-inc","modality":"Small molecule","firstApprovalDate":"","aiSummary":"AV-001 is a small molecule that targets the PI3K pathway to modulate immune responses. Used for Metastatic non-small cell lung cancer, PD-L1 positive, Metastatic melanoma.","enrichmentLevel":3,"visitCount":1,"trialStats":{"total":2,"withResults":0},"verificationStatus":"verified","dataCompleteness":{"mechanism":true,"indications":true,"safety":true,"trials":true,"score":4}}